Walkersville, MD (PRWEB) May 13, 2011
Lonza will offer a live Webinar on the benefits and value of implementing MODA™—a paperless QC Micro solution by Lonza—on Tuesday, June 7, 2011 at 8:00 AM EST or 11:00 AM EST.
The presentation will feature Dominick Villani, Manager of QC Microbiology at Amylin Pharmaceuticals, a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines.
Webinar topics will include:
- Industry Best Practices, Strategies, and Regulatory Guidelines
- Definitions of Qualification, Re-qualification and Routine Monitoring
- Use of Automation and the MODA™ Solution to Meet Requirements
- Tracking, Trending, and Report Generation Compliance Using MODA™ Solution
This webinar will discuss and demonstrate QC automation best practices to implement and maintain a robust and compliant aseptic gowning monitoring program.
To register, visit http://www.tmecom.com/lonza/webinars/060711/registration.html
Paper-based processes still burden most QC Micro programs: paper scheduling, sharpie pen labeling of sample media, manual reconciliation, paper log book entry, and manual notification on deviations. These steps are labor-intensive, time consuming, and yield duplication of tasks and high error rates. Amylin has successfully implemented MODA™—a paperless QC Micro solution by Lonza. As a result, Amylin is achieving their goal to automate their QC processes and regulatory compliance at their manufacturing facility.
About MODA™ Solution
More science. Less paper.™ The MODA™ solution strengthens Lonza’s overall Rapid Testing Solutions platform by adding a complementary product offering for quality assurance (QA) and quality control (QC) organizations in the life science industry. The MODA™ solution offers automated data collection, workflow management, on demand analytics and visualization of regulated manufacturing processes, including environmental monitoring (EM), utility testing, and product testing. The MODA™ solution eliminates inefficiencies and reduces error rates inherent with paper-based systems. Further information can be found at http://www.lonza.com/moda
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at http://www.lonza.com